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Preterm birth, defined as the birth of an infant prior to 
37 weeks completed gestation, continues to be the leading 
cause of perinatal morbidity and mortality.  In 2003, over 
$18 billion in hospital charges were attributed to infants 
with any diagnosis of prematurity or low birthweight. 
The long-term health care visits, medications and lost 
productivity of parents are not included in this cost.1  In 
the United States the preterm birth rate is estimated at 
12.6%, or roughly 500,000 births annually.  Although the 
rate is slightly lower in Iowa (Figure 1), this number is on 
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the rise.1  Iowa experienced a 22% increase in the rate of 
preterm birth over the ten year period from 1994-2004.  
Prevention of preterm birth continues to be a priority 
in the United States.  Healthy People 2010, a set of Fed-
eral health objectives for the new millennium, set a goal 
of no more than 7.6% preterm births by the year 2010. 
Based on the above statistics, this seems to be an unat-
tainable goal.  Before we can identify the interventions to 
reverse this increasing prematurity rate, let’s first review 
the causes of prematurity.   
The Rising Pre-term Delivery Rate in Iowa— 
Three Things We Can Do Now
2Prematurity—A Complex Problem
The etiology of preterm birth is multifactorial.  Sponta-
neous (or physiologic) preterm birth differs from induced 
(iatrogenic).  Approximately two-thirds of the preterm 
births in the U.S. are spontaneous.  Lockwood proposed 
four major etiologies of spontaneous prematurity: infec-
tion or inflammation (1), pathologic uterine distension (2), 
activation of the maternal-fetal hypothalamic-pituitary-
adrenal (HPA) axis (3), and uterine bleeding or abruption 
(4).2  Premature rupture of membranes accounts for many 
of the births associated with infection and inflammation; 
multiple gestations contribute to uterine over-distension. 
Maternal smoking and drug use increase the risk of pla-
cental abruption and activate the maternal-fetal HPA axis. 
Iatrogenic, or medically indicated, preterm births ac-
count for the majority of the additional number of preterm 
births in the last ten years.3  Figure 2 shows the yearly 
changes in preterm birth subtypes relative to the rate in 
1989.  
Prematurity—Current Treatment Recommendations 
In order to have patients present at term it is impor-
tant to make a timely diagnosis of preterm labor.  Pa-
tient complaints of uterine pressure, vaginal discharge, 
cramping or low backache should prompt evaluation 
for uterine contractions and also a check of the state 
of the cervix.  The goal is to make a timely diagnosis 
of threatened preterm labor in order that tocolytic, ste-
roid and antibiotic therapy might be initiated without 
delay and when appropriate arrangements for transfer 
of the patient can also be made.  
Tocolytics
The efficacy of tocolytics to quiet uterine contrac-
tions can, at best, be described as fair to modest.  Toco-
lytics may be successful at inhibiting contractions for a 
short period of time (2 days or less).  The major benefit 
in prolonging pregnancy with short-term tocolysis is 
to gain time so that corticosteroids can be administered 
to enhance fetal lung maturation and, if necessary, to 
transfer the woman to a facility with a neonatal inten-
sive care unit.  The benefits of prolonging pregnancy 
for longer than two days have not been clarified.  
Tocolytic therapy is not without the risk of side ef-
fects to the mother.  Calcium channel blockers seem 
to have the lowest fetal and maternal side effects. 
Because of this side effect profile and effectiveness, 
Nifedipine is now being used as the first-line toco-
lytic therapy at the University of Iowa.  Magnesium 
sulfate has a significant risk of pulmonary edema and 
muscle weakness, without evidence to show improved 
neonatal outcomes.  Beta-mimetics result in significant 
maternal hyperglycemia and cardiac toxicity, while 
non-steroidal anti-inflammatory drugs (NSAIDs) pose 
fetal effects of oligohydramnios and premature closure 
of the ductus arteriosus.  Dual tocolytic therapy can 
lead to synergistic maternal side effects and should be 
used with extreme caution.  Pregnancies continue to be 
at risk for premature delivery following the 48 hours 
of acute corticosteroid and tocolytic administration. 
However, maintenance of tocolytic therapy beyond 
this time period shows no prolongation of gestational 
age or increased birth weight at delivery in most stud-
Figure 1. Premature births as percentage of total live births.1
3ies.  Use of tocolytic therapy beyond this initial 48 hour 
period therefore should not be routine.  
Antibiotics
While inflammation and subclinical infection likely 
play a role in many cases of preterm labor, administra-
tion of antibiotics has not been effective in preventing 
or delaying preterm delivery.4  The only exceptions 
to this rule are in the cases of asymptomatic bacteriu-
ria and preterm premature rupture of membranes in 
which cases antibiotic therapy should be given.  Group 
B strep known positivity should also be treated if the 
patient is in preterm labor.  If the GBS status is un-
known, cultures should be obtained and then initiation 
of prophylaxis should occur until the culture results 
are known.  Bacterial vaginosis (BV) has been studied 
extensively due to its association with increased risk 
of preterm delivery.  However, there have been con-
flicting data on whether treatment of BV will decrease 
the risk of premature delivery.  Based on the evidence 
available to date, it does not seem that treatment will 
change a woman’s risk for early delivery.4  Currently, 
neither ACOG nor the CDC recommends screening as-
ymptomatic women for BV.  
Corticosteroids 
Corticosteroids accelerate fetal pulmonary maturity 
by increasing surfactant manufacturing and release. 
For women in spontaneous premature labor, or those 
whom are expected to have an iatrogenic premature 
delivery, the benefits of antenatal corticosteroids are 
quite remarkable.  Reductions in neonatal mortality, 
respiratory distress syndrome (RDS) and intraventric-
ular hemorrhage (IVH) are well-demonstrated over a 
broad gestational age range (24 to 34 weeks).5   These 
advantages are seen regardless of maternal race, ma-
ternal age or fetal gender.   In the presence of prema-
ture rupture of membranes, antenatal corticosteroids 
have been shown to have benefit between 24 and 34 
weeks gestation, mainly due to a reduction of RDS, 
IVH and neonatal death.   The greatest benefit of ste-
roids has been shown to occur in the 7 days following 
administration, but some benefit occurs within the first 
24 hours.   Either betamethasone (two doses) or dex-
amethasone (four doses) can be used.  Although there 
has been some concern that betamethasone should be 
used preferentially due to its reduction in both mortal-
ity and periventricular leukomalacia, ACOG has not 
found sufficient evidence to recommend one treatment 
over the other.6 
Whether antenatal corticosteroids lead to an in-
creased risk of infection for either the mother or ne-
onate is still unclear.  In cases of fulminant maternal 
infection or chorioamnionitis, administration of corti-
costeroids would not be recommended.  However, in 
most other cases, the risks associated with prematurity 
are much greater than the risk of neonatal infection. 
Multiple courses of administration are not recom-
Figure 2. Yearly change in percent of preterm birth.1
4mended, due to the increased risk of low birth weight 
and fetal adrenal suppression.7  A single repeated 
course of corticosteroids may offer some improvement 
in neonatal pulmonary function; however, more inves-
tigation is needed to determine whether the benefit 
outweighs the risk.  In follow-up studies of children 
up to age twelve, there was no evidence to indicate that 
antenatal corticosteroids adversely affected physical or 
neurologic development.  
Prematurity—A Preventable Problem?
Although preterm birth is multifactorial, there are a 
few interventions that would benefit specific obstetric 
populations to minimize their risk of preterm delivery. 
We  recommend three practices that will have a posi-
tive impact on the increasing pre-term delivery rate in 
Iowa; (1) adopt a zero tolerance policy for any elective 
delivery before 39 0/7 weeks based on good OB dat-
ing, (2) utilize Progesterone therapy in woman who 
have a history of pre-term birth, and (3) increase our 
efforts to diminish exposure to cigarette smoke, both 
primary smoke and second-hand smoke. 
(1) Adopt a zero tolerance policy for any elective 
delivery before 39 0/7 weeks based on good OB 
dating.   
This is an area where we as obstetricians may be 
able to intervene to decrease the prematurity rate.  The 
maternal morbidity associated with a pregnancy com-
plication must be significantly serious to necessitate a 
delivery prior to 39 weeks gestation.  Temperature in-
stability, increased risk of infection and poor feeding 
habits are issues facing infants born between 37 and 39 
weeks gestation.  Significant brain and neurologic de-
velopment continue to occur in the last month of preg-
nancy, with the fetal brain nearly doubling in weight 
from 35 to 40 weeks gestation.8   The confirmation of 
lung maturity through amniocentesis can minimize 
the risk of respiratory distress syndrome, but fetal lung 
maturity testing does not assess for any of the other 
risks of prematurity.  Although the risk to the individ-
ual infant may be small, given the increasing number 
of “late” (34 to 36 6/7 weeks gestation) preterm deliv-
eries, the overall impact to society is large.  Increased 
neonatal intensive care admissions and longer hospi-
tal stays for late preterm infants are a significant cost 
to the medical system.  Data supporting the increased 
neonatal morbidity associated with elective repeat Ce-
sarean prior to 39 weeks was presented at the national 
meeting for the Society for Maternal Fetal Medicine in 
February 2008.  This data is expected to be published 
soon.  
The ACOG Technical bulletin on induction of la-
bor lists only a few maternal indications for induction 
prior to 39 weeks gestation (Figure 3).9  With adequate 
surveillance and treatment, both chronic hypertension 
and diabetes (pre-gestational or gestational), can often 
be managed until 39 weeks gestation.  Repeat Cesar-
ean sections should be completed at 39 weeks or af-
ter, unless a prior Classical Cesarean was performed. 
A woman with contractions prior to 39 weeks should 
clearly be in labor (cervical change with contractions) 
prior to proceeding with a repeat Cesarean.  The desire 
to avoid uterine rupture is understood, but this risk is 
low (approximately 0.7%) for women with a prior low 
transverse Cesarean section in spontaneous labor.10  
As physicians we must be honest about our indi-
cations for inductions that occur at any time in preg-
nancy, but particularly if those inductions occur before 
39 weeks.  Some examples that we have encountered 
as the Iowa Statewide Perinatal Care Team travels the 
State of Iowa include: 
Example 1:  A patient was scheduled for induction 
after a “deceleration of the fetal heart rate” was seen on 
NST in the office during her routine prenatal visit.  But 
the induction was scheduled for the next day with no 
intervening testing of the fetus.  Obviously this would 
not be the appropriate course of action if a deceleration 
had been seen.  The patient should have been sent di-
rectly to L&D for further monitoring and assessment. 
If further decelerations are seen, immediate delivery 
may be warranted.  Having the patient show up the 
next morning for a scheduled induction is not appro-
priate if a deceleration had really been documented the 
previous day. 
Example 2:  The patient is being induced for “a touch 
of the pressures” or “possible mild preeclampsia.” 
However, no work up for PIH or preeclampsia is ever 
done, no 24 hour urine and no preeclampsia laboratory 
evaluation.  Preeclampsia and/or PIH may be legiti-
mate reasons for induction prior to 39 weeks, but the 
diagnosis must be supported by the medical record. 
Example 3:  We have also observed cases where the 
L&D personnel are given an indication for the induc-
tion, but when the admitting nurse asks the patient 
why they are being induced, the patient has no idea, 
and says something to the effect, “I don’t know, the 
doctor just told me to show up today for induction.” 
Of course this is suggestive of poor doctor-patient 
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Figure 3. Indications for Induction of Labor 
 
As physicians we must be honest about our indications for inductions that occur at any 
ti e in pregnancy, but particularly if those inductions occur before 39 weeks.  Some 
examples that we have encountered as the Iowa Statewide Perinatal Care Team travels 
the State of Iowa include:  Example 1:  A patient was scheduled for induction after a 
“deceleration of the fetal heart rate” was seen on NST in the office during her routine 
prenatal visit.  But the induction was scheduled for the next day with no intervening 
testing of the fetus.  Obviously this would not be the appropriate course of action if a 
deceleration had been seen.  The patient sh uld have been sent directly to L&D for 
further monitoring and assessment.  If further decelerations are seen, immediate delivery 
may be warranted.  Having the patient show up the next morning for a scheduled 
induction is not appropriate if a deceleration had really been documented the previous 
day.  Example 2:  The patient is being induced for “a touch of the pressures” or “possible 
mild preeclampsia”.  However, no work up for PIH or preeclampsia is ever done, no 24 
hour urine a d no preeclampsia laboratory evaluation.  Preeclampsia and/or PIH may be 
legiti ate reasons for induction prior to 39 weeks, but the diagnosis must be supported 
by the medical record.  Example 3:  We have also observed cases where the L&D 
personnel are given an indication for the induction, but when the admitting nurse asks the 
patient why they are being induced, the patient has no idea, and says something to the 
effect, “I don’t know, the doctor just told me to show up today for induction”.  Of course 
this is suggestive of poor d ctor-patient communication.  If we can see through these 
at empts in ou brief review f recor s, in cas  of a bad outcome, a plaintiffs expert 
witness, who gets paid by the hour and therefore has no motivation to do a quick review, 
will clearly see through these inappropriate attempts to justify an early induction.  We 
must practice safe, good and honest medicine, not only for our patients safety but for our 
integrity.  You can imagine the guilt that will be felt by both the healthcare provider and 
the mother if there is a bad outcome after an inappropriate early induction that was 
perform d for social rea ons alone. 
 
(2) Utilize Progesterone therapy in woman who have a history of pre-term birth. 
Women with a history of preterm delivery are at two to three times the risk of having a 
recurrent preterm delivery.  For these women another option is available to decrease their 
risk of prematurity – 17 alpha-hydroxyprogesterone caproate (17-P).  The exact 
mechanism by which 17-P works is not clearly understood but it is thought to be related 
to a reduction of gap junction formation and herefore decreased uterine contractions11.   
It has recently bee  proposed that its effect also may be anti-inflammatory in nature and 
Figure 3. Indications for Induction of Labor
5in our brief review of records, in case of a bad outcome, 
a plaintiffs expert witness, who gets paid by the hour 
and therefore has no motivation to do a quick review, 
will clearly see through these inappropriate attempts 
to justify an early induction.  We must practice safe, 
good and honest medicine, not only for our patients 
safety but for our integrity.  You can imagine the guilt 
that will be felt by both the healthcare provider and the 
mother if there is a bad outcome after an inappropriate 
early induction that was performed for social reasons 
alone.
(2) Utilize Progesterone therapy in woman who have 
a history of pre-term birth.
Women with a history of preterm delivery are at two 
to three times the risk of having a recurrent preterm de-
livery.  For these women another option is available to 
decrease their risk of prematurity—17 alpha-hydroxy-
progesterone caproate (17-P).  The exact mechanism by 
which 17-P works is not clearly understood but it is 
thought to be related to a reduction of gap junction for-
mation and therefore decreased uterine contractions.11 
It has recently been proposed that its effect also may be 
anti-inflammatory in nature and that it may preserve 
cervical integrity.  Initially studied as a 250 mg weekly 
injection, 17-P was found to decrease the rate of pre-
term delivery (less than 37 weeks) from 55 % in the pla-
cebo group to 36% in the treatment group.12   In addi-
tion, infants of the treatment group were significantly 
less likely to have necrotizing enterocolitis, intraven-
tricular hemorrhage or need supplemental oxygen. 
Administration of 17-P was initiated at 16-20 weeks 
gestation in the initial study.  Although this is when 
we begin administration at UIHC, the optimal timing 
to initiate therapy has not been well-established.  
Follow-up studies have evaluated the use of 17-P in 
differing routes of administration and study popula-
tions.  Since many women would like to avoid injec-
tions and because 17-P is not widely marketed by any 
particular pharmaceutical company, other routes of 
administration have been investigated.  Prophylactic 
administration of progesterone in the form of a vaginal 
suppository (100 mg qhs) was found to significantly 
reduce the risk of prematurity (by approximately 50%) 
in women who had had a prior preterm delivery.13 
Although this may be a more convenient form for pa-
tients due to self-administration, it is not widely avail-
able and must be formulated by individual pharma-
cies.  A study is currently underway to evaluate the use 
of vaginal progesterone suppositories in women with 
a history of prior preterm birth, but with normal cervi-
cal lengths during the current pregnancy.  For women 
with no history of a preterm birth, but a shortened 
(≤15 mm) cervix, it appears that progesterone sup-
positories may be beneficial.14    As for twin gestations, 
treatment with prophylactic 17-P does not seem to re-
duce the risk of preterm delivery.15  This is likely due 
to the different mechanism (uterine over distension) 
to which many twin premature deliveries are thought 
to be attributed.  Currently, ACOG recommends that 
the use of progesterone supplementation in pregnancy 
to prevent preterm birth be restricted to women with 
a history of a prior spontaneous preterm delivery.16 
However, the ideal population, route and timing of 
progesterone therapy are yet to be confirmed.  
(3) Increase our efforts to diminish exposure to 
cigarette smoke, both primary smoke and second-
hand smoke.
Although preterm birth is multifactorial, there are a 
few interventions that would benefit specific obstetric 
populations to minimize their risk of preterm delivery. 
In Iowa, 23.2% of childbearing aged women smoke 
tobacco (March of Dimes website).  Although fewer 
women smoke during pregnancy, efforts at smoking 
cessation could still offer significant benefits.  Not 
only would the risk of preterm delivery be decreased 
by approximately 17%, but the complications of low 
birth weight, intrauterine fetal demise, neonatal death, 
premature rupture of membranes, placental abruption, 
and placenta previa would be significantly reduced as 
well.17,18   
Iowans have an advantage when attempting to 
quit smoking.  Quitline Iowa is a statewide toll-free 
smoking cessation hotline at 866-U-CAN-TRY (866-
822-6879). This service is available 8 a.m. to midnight, 
seven days a week.  Staffed by trained counselors from 
the Iowa Tobacco Research Center, Quitline Iowa of-
fers callers state-of-the-art smoking cessation services 
over the phone.  Callers also can request free materials 
to be sent in the mail, or referrals to smoking cessa-
tion resources in their community, including support 
groups, clinics, and consultants.  
Environmental exposure to smoke is also associated 
with adverse pregnancy outcomes, including preterm 
delivery.19,20  Iowa currently has no statewide policy re-
garding smoking.  Rather, the law allows most business 
owners to choose their own smoking policies.  Only 
recently (July 2006) did the University of Iowa Hos-
pitals and Clinics campus become “smoke-free,” with 
the whole campus becoming smoke-free on January 
2009.  Our patients could benefit from state and hospi-
tal policies to limit their exposure to tobacco smoke in 
public places.  The Iowa legislature has made the 2008 
year the “Year of Health” and as such will consider 
several pieces of legislation this year dealing with vari-
ous health issues.  One of these pieces of legislation is 
a bill that would ban smoking in public buildings and 
workplaces.  We support and encourage passage of the 
“Smokefree Air Act.”  
6Prematurity—An Important Problem
Preterm labor is a multifactorial syndrome with 
complex and incompletely understood pathophysiol-
ogy.  This complexity challenges our efforts for pre-
vention.  While there are subpopulations of women for 
whom preterm delivery can be prevented, it remains 
important to delay delivery of very preterm infants 
whenever possible. Research efforts will continue to 
guide our therapies as greater understanding of the 
process is gained.  Until we learn otherwise, we should 
continue to promote smoking cessation for all of our 
patients and offer 17-P to those with a history of pre-
term delivery.  
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Who? Women with a history of "1 
spontaneous preterm delivery 
? Possibly women with a 
shortened cervix 
NOT twins 
NOT current preterm labor 
When? Start: 16-20 weeks gestation 
End: 36 weeks gestation 
How?  250 mg IM weekly OR 100 mg 
vaginal suppository nightly 
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